Merck KGaA CFO Helene von Roeder discusses the group's third-quarter earnings and its progress with drug trials.

Germany’s Merck KGaA expects annual sales to be at the lower half of its outlook range after third-quarter sales missed ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

Investing.com -- Shares of Merck KGaA (ETR: MRCG) fell over 4% on Thursday following a mixed reception to its third-quarter ...

(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

BusinessWire India Accra [Ghana] Mumbai Maharashtra [India] November 14 Merck Foundation the philanthropic arm of Merck KGaA ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...